

Medtronic

ESC Guidelines recommend renal denervation



for uncontrolled and resistant hypertension patients¹

The future of hypertension care is now.


The European Society of Cardiology now includes renal denervation (RDN) as a class IIb recommendation that provides a safe and effective complementary option to control blood pressure.¹

Patient Selection criteria

Uncontrolled hypertension

-  With increased CV risk
-  Treated with <3 antihypertensive drugs


Resistant hypertension


-  Treated with ≥ 3 antihypertensive drugs including diuretic

And who have:

- eGFR ≥ 40 ml/min/1.73m²
- Express a preference for RDN in a shared-decision making process

Additional recommendations

-  Selection of patients should be done after assessment by a multidisciplinary team.

-  Procedure should be performed in experienced medium to high volume centers.

[Read the ESC guidelines](#)

Elevate hypertension care options as you know them.

The Symplicity™ blood pressure procedure delivers **significant, safe, and sustained blood pressure reductions.**²⁻⁶

Explore the evidence

References:

1. McEvoy JW, et al, European Heart Journal, ehae178, <https://doi.org/10.1093/eurheartj/ehae178>
2. Böhm M, et al. Lancet. 2020;395:1444-1451.
3. Kandzari DE, et al. J Am Coll Cardiol. 2023;82:1809-1823.
4. Mahfoud F, et al. Lancet. 2022;399:1401-1410.
5. Mahfoud F, et al. EuroPCR 2023.
6. Mahfoud F, et al. Hypertension. 2023;80:1759-1770.

This material should not be considered the exclusive source of information, it does not replace or supersede information contained in the device manual(s).

Please note that the intended use of a product may vary depending on geographical approvals. See the device manual(s) for detailed information regarding the intended use, the implant procedure, indications, contraindications, warnings, precautions, and potential adverse events. For a MRI compatible device(s), consult the MRI information in the device manual(s) before performing a MRI.

If a device is eligible for eIFU usage, instructions for use can be found at Medtronic's website manuals.medtronic.com. Manuals can be viewed using a current version of any major internet browser. For best results, use Adobe Acrobat® Reader with the browser.

Medtronic products placed on European markets bear the CE mark and the UKCA mark (if applicable). For any further information, contact your local Medtronic representative and/or consult Medtronic's websites.

2024-esc-2024-one-pager-summary-en-gb-emea-14240073 ©2024 Medtronic. Medtronic logo and Engineering the extraordinary are trademarks of Medtronic. Third party brands are trademarks of their respective owners. All other brands are trademarks of a Medtronic company. For distribution only in markets where the Symplicity Spyral™ multi-electrode renal denervation catheter and Symplicity G3™ renal denervation RF generator have been approved. Not for distribution in the USA, Japan, or France.

Medtronic

Europe

Medtronic International Trading Sàrl.
Route du Molliau 31
Case postale
CH-1131 Tolochenaz
www.medtronic.eu
Tel: +41 (0)21 802 70 00
Fax: +41 (0)21 802 79 00

United Kingdom/Ireland

Medtronic Limited
Building 9
Croxley Park
Hatters Lane
Watford
Herts WD18 8WW
www.medtronic.co.uk
Tel: +44 (0)1923 212213
Fax: +44 (0)1923 241004

© Medtronic 2024.
All rights reserved.



> 9

mmHg

reduction in OSBP in patients off and on medications^{2,3}

